Skip to main content
. 2021 Dec 28;126(6):889–898. doi: 10.1038/s41416-021-01679-1

Fig. 2. Response to ICI according to BRAF mutation class, TMB and PD-L1 status.

Fig. 2

a Waterfall plot illustrating individual responses of patients treated with ICI with available scans assessed by RECIST. Boxes below indicate BRAF mutation Class (I–III indicates class), PD-L1 expression and tumour mutation burden (TMB). The best overall response was coded as progression of disease (PD), stable disease (SD), partial response (PR) or complete response (CR). b Overall survival of patients across all classes of BRAF-altered tumours in patients who received ICI versus those who never received ICI. c Overall survival of patients with Class I–III BRAF-altered tumours who received ICI versus those who never received ICI. d Overall survival from the time of first immunotherapy treatment by line of therapy at which ICI was received. e Overall survival of patients with Class I-mutant lung cancers who received ICI versus those who never received ICI. f Overall survival of patients whose cancers had Class II/III BRAF alterations who received ICI versus those who never received ICI.